Paul Paik, MD
Enriched profileThoracic Medical Oncologist and Clinical Director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center · Memorial Sloan Kettering Cancer Center
Paul Paik is Thoracic Medical Oncologist and Clinical Director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center at Memorial Sloan Kettering Cancer Center. OpenAlex indexes 460 publications with 19,030 citations (h-index 46); ClinicalTrials.gov lists 11 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 16 Oct 2026
Paul Paik, MD, is Thoracic Medical Oncologist and Clinical Director, Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center. The public record shows 460 publications with 19,030 citations (h-index 46), centered on Lung Cancer Treatments and Mutations, Lung Cancer Research Studies, Lung Cancer Diagnosis and Treatment. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 8 companies, 1 NIH-funded awards (2021–2023).
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Lung Cancer Treatments and Mutations
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 8 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 13 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 94.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
- A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
- Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
Sponsor: SWOG Cancer Research Network
- A Study of ZEN003694 in People With Squamous Cell Lung Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
Industry payments
Updated 16 Oct 2026
8 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- EMD Serono, Inc.Program year20255 payments$32,607openpaymentsdata.cms.gov ↗
- EMD Serono Research & Development Institute, Inc.Program year20251 payment
- ABBVIE INC.Program year20256 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
22.5%Kinase inhibitor22.5%Tagrisso70%Erlotinib Hcl18%Alecensa12%Part D<11 patientsMetabolism & gastrointestinal
21.4%Corticosteroid12.6%Prednisone100%Part D≥30 patientsSerotonin-3 Receptor Antagonist6.4%Ondansetron Hcl100%Part D≥19 patients+ 1 more class in this area
Sensory organs
17.3%Corticosteroid17.3%Dexamethasone84%Alclometasone Dipropionate16%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
1 NIH research award on record, funded 2021–2023 per NIH RePORTER. The latest:
- A Phase 1 Trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in Advanced NSCLC Patients
Sloan-Kettering Inst Can Research
FY2023$581,481R01CA255639 - A Phase 1 Trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in Advanced NSCLC Patients
Sloan-Kettering Inst Can Research
FY2022$591,444R01CA255639 - A Phase 1 Trial of MLN0128 (sapanisertib) and CB-839 HCl (telaglenastat) in Advanced NSCLC Patients
Sloan-Kettering Inst Can Research
FY2021$628,641R01CA255639
Congress activity
Updated 16 Oct 2026
84 congress contributions (2010–2026) across AACR, ASCO, ASTRO, ENDO, ESMO per OpenAlex. The most recent:
- Petosemtamab plus pembrolizumab as first-line (1L) treatment of PD-L1 high metastatic non-small cell lung cancer (NSCLC): Global phase 2 trial.
ASCO Annual Meeting
ASCO2026Presenting author - Profiling patients with <i>MET</i> exon 14 ( <i>MET</i> ex14) skipping NSCLC with a sustained clinical benefit to tepotinib in VISION.
ASCO Annual Meeting
ASCO2026Presenting author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.
Journal of clinical oncology
Article2026 - Presenting Features and Causes of Diagnostic Delays: A Report From the NUT Carcinoma Registry.
JCO precision oncology
Article2025 - Phase I Clinical Trial of the Bifunctional EGFR/TGF-β Fusion Protein Ficerafusp Alfa (BCA101) Alone and in Combination with Pembrolizumab for Advanced Solid Tumors.
Clinical cancer research
Clinical Trial2025 - Molecular Characterization of NUT Carcinoma: A Report from the NUT Carcinoma Registry.
Clinical cancer research
Article2025 - Liquid and Tissue Biopsies for Identifying MET Exon 14 Skipping NSCLC: Analyses from the Phase II VISION Study of Tepotinib.
Clinical cancer research
Clinical Trial2025
Most-cited works
by citation count (OpenAlex)- 01Comprehensive genomic characterization of squamous cell lung cancersArticle4,041 citations2012
- 02OncoKB: A Precision Oncology Knowledge BaseArticle2,723 citations2017
- 03Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping MutationsArticle870 citations2020
- 04Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring <i>BRAF</i> MutationsArticle692 citations2011
- 05
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/paul-paik-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - Other
synapse.mskcc.org/synapse/people/5341-Paul_Paik
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →synapse.mskcc.org ↗ - ResearchGate
researchgate.net/scientific-contributions/Paul-K-Paik-16299303
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
metcrusaders.org/team/dr-paul-paik
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →metcrusaders.org ↗ - Other
onclive.com/authors/paul-k-paik-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - Other
patientpower.info/bio/paul-k-paik-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →patientpower.info ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →vivo.weill.cornell.edu ↗
- Board certified
Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗ - Board certified
Medical Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
Secondary affiliations
appointments beyond the home institution- Associate Professor of Clinical Medicine
Weill Cornell Medical College
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vivo.weill.cornell.edu ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mskcc.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →patientpower.info ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
Mark Kris, MD
Memorial Sloan Kettering Cancer Center
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center